drugset / Trial / NCT02468830

Pilot Study of Mirabegron in Pediatric Patients With Overactive Bladder

NCT02468830

Phase 3 Completed 58 enrolled CHU de Quebec-Universite Laval
NaSingle-groupOpen-labelTreatment

Summary

The objective is to evaluate the efficacy and safety of mirabegron to treat urinary incontinence in children with Overactive Bladder that are refractory and/or intolerant to antimuscarinics.

Timeline

Start
2013-04
Primary completion
2016-01
Completion
2016-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Mirabegron Other / unclassified 25 mg
Subject Mirabegron Other / unclassified 50 mg

Indications